Literature DB >> 23132766

Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.

M S Anglesio1, Y Wang, W Yang, J Senz, A Wan, A Heravi-Moussavi, C Salamanca, S Maines-Bandiera, D G Huntsman, G B Morin.   

Abstract

Our group recently described recurrent somatic mutations of the miRNA processing gene DICER1 in non-epithelial ovarian cancer. Mutations appeared to be clustered around each of four critical metal-binding residues in the RNase IIIB domain of DICER1. This domain is responsible for cleavage of the 3' end of the 5p miRNA strand of a pre-mRNA hairpin. To investigate the effects of these cancer-associated 'hotspot' mutations, we engineered mouse DICER1-deficient ES cells to express wild-type and an allelic series of the mutant DICER1 variants. Global miRNA and mRNA profiles from cells carrying the metal-binding site mutations were compared to each other and to wild-type DICER1. The miRNA and mRNA profiles generated through the expression of the hotspot mutations were virtually identical, and the DICER1 hotspot mutation-carrying cells were distinct from both wild-type and DICER1-deficient cells. Further, miRNA profiles showed that mutant DICER1 results in a dramatic loss in processing of mature 5p miRNA strands but were still able to create 3p strand miRNAs. Messenger RNA (mRNA) profile changes were consistent with the loss of 5p strand miRNAs and showed enriched expression for predicted targets of the lost 5p-derived miRNAs. We therefore conclude that cancer-associated somatic hotspot mutations of DICER1, affecting any one of four metal-binding residues in the RNase IIIB domain, are functionally equivalent with respect to miRNA processing and are hypomorphic alleles, yielding a global loss in processing of mature 5p strand miRNA. We further propose that this resulting 3p strand bias in mature miRNA expression likely underpins the oncogenic potential of these hotspot mutations.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23132766     DOI: 10.1002/path.4135

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  62 in total

1.  Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.

Authors:  Elke Pfaff; Christian Aichmüller; Martin Sill; Damian Stichel; Matija Snuderl; Matthias A Karajannis; Martin U Schuhmann; Jens Schittenhelm; Martin Hasselblatt; Christian Thomas; Andrey Korshunov; Marina Rhizova; Andrea Wittmann; Anna Kaufhold; Murat Iskar; Petra Ketteler; Dietmar Lohmann; Brent A Orr; David W Ellison; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Andreas von Deimling; Peter Lichter; Marcel Kool; Marc Zapatka; Stefan M Pfister; David T W Jones
Journal:  Acta Neuropathol       Date:  2019-11-25       Impact factor: 17.088

Review 2.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

3.  Germ-line and somatic DICER1 mutations in pineoblastoma.

Authors:  Leanne de Kock; Nelly Sabbaghian; Harriet Druker; Evan Weber; Nancy Hamel; Suzanne Miller; Catherine S Choong; Nicholas G Gottardo; Ursula R Kees; Surya P Rednam; Liselotte P van Hest; Marjolijn C Jongmans; Shalini Jhangiani; James R Lupski; Margaret Zacharin; Dorothée Bouron-Dal Soglio; Annie Huang; John R Priest; Arie Perry; Sabine Mueller; Steffen Albrecht; David Malkin; Richard G Grundy; William D Foulkes
Journal:  Acta Neuropathol       Date:  2014-07-15       Impact factor: 17.088

Review 4.  MicroRNA biogenesis pathways in cancer.

Authors:  Shuibin Lin; Richard I Gregory
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

5.  Reply: Serum microRNA screening for DICER1-associated pleuropulmonary blastoma.

Authors:  Kris Ann P Schultz; Anne Harris; Gretchen M Williams; Shari Baldinger; Leslie Doros; Patricia Valusek; A Lindsay Frazier; Louis P Dehner; Yoav Messinger; D Ashley Hill
Journal:  Pediatr Blood Cancer       Date:  2014-09-22       Impact factor: 3.167

6.  Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1.

Authors:  Douglas R Stewart; Ana F Best; Gretchen M Williams; Laura A Harney; Ann G Carr; Anne K Harris; Christian P Kratz; Louis P Dehner; Yoav H Messinger; Philip S Rosenberg; D Ashley Hill; Kris Ann P Schultz
Journal:  J Clin Oncol       Date:  2019-02-04       Impact factor: 44.544

7.  Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.

Authors:  Steven Klein; Hane Lee; Shahnaz Ghahremani; Pamela Kempert; Mariam Ischander; Michael A Teitell; Stanley F Nelson; Julian A Martinez-Agosto
Journal:  J Med Genet       Date:  2014-03-27       Impact factor: 6.318

8.  Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model.

Authors:  Mark Brenneman; Amanda Field; Jiandong Yang; Gretchen Williams; Leslie Doros; Christopher Rossi; Kris Ann Schultz; Avi Rosenberg; Jennifer Ivanovich; Joyce Turner; Heather Gordish-Dressman; Douglas Stewart; Weiying Yu; Anne Harris; Peter Schoettler; Paul Goodfellow; Louis Dehner; Yoav Messinger; D Ashley Hill
Journal:  F1000Res       Date:  2015-07-10

Review 9.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

10.  Characterization of a naturally occurring truncated Dicer.

Authors:  Nicola Mosca; Julia Starega-Roslan; Filomena Castiello; Aniello Russo; Wlodzimierz J Krzyzosiak; Nicoletta Potenza
Journal:  Mol Biol Rep       Date:  2015-04-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.